Prostate cancer is the 2nd most common cancer in men.
1 IN 8 MEN WILL GET IT IN THEIR LIFETIME…
…but prostate cancer diagnosis and treatment have major limitations.
The ClariCore Biopsy System uses AI-powered Spectroscopy to classify tissue as benign or suspicious in real time during a prostate biopsy.
In a standard biopsy, tissue samples are taken randomly from the prostate and evaluated by pathology. This approach can miss almost half of all cancers.
With ClariCore, a needle is inserted and, before tissue samples are taken, spectroscopy is performed. Integrated fiber optics shine light of specific wavelengths into the tissue.
The returned light is instantaneously analyzed by a spectrometer and an AI algorithm, classifying the tissue as benign or suspicious. This has the potential to find more cancers.
In a 144 patient multi-center study, ClariCore was shown to have very high accuracy in classifying tissue:
NEGATIVE PREDICTIVE VALUE